Table 1. Comparison of the incidence of... | American Society of Hematology

Table 1.

Comparison of the incidence of factor V mutations in the PROWESS*study to the general population

	Incidence of factor V mutation
	FV Leiden	FV Cambridge	FV Hong Kong
PROWESS study
*All patients†*	*4.1% (65/1601)*	*0.13% (2/1582)*	*0.06% (1/1582)*
Caucasians	4.6% (61/1315)	0.15% (2/1301)	0% (0/1301)
*Western Asians‡*	*9.1% (1/11)*	*0% (0/10)*	*0% (0/10)*
East/Southeast Asians	0% (0/18)	0% (0/17)	5.9% (1/17)
General population^7,32,33,47
*Caucasians*	*4%-6%*	*Rare (<0.5%)*	*Rare^8,33*
Western Asians	2%-4%	None reported⁸	None reported³³
*East/Southeast Asians*	*∼0%*	*None reported^8,9*	*3%-5%*

	Incidence of factor V mutation
	FV Leiden	FV Cambridge	FV Hong Kong
PROWESS study
*All patients†*	*4.1% (65/1601)*	*0.13% (2/1582)*	*0.06% (1/1582)*
Caucasians	4.6% (61/1315)	0.15% (2/1301)	0% (0/1301)
*Western Asians‡*	*9.1% (1/11)*	*0% (0/10)*	*0% (0/10)*
East/Southeast Asians	0% (0/18)	0% (0/17)	5.9% (1/17)
General population^7,32,33,47
*Caucasians*	*4%-6%*	*Rare (<0.5%)*	*Rare^8,33*
Western Asians	2%-4%	None reported⁸	None reported³³
*East/Southeast Asians*	*∼0%*	*None reported^8,9*	*3%-5%*

Patients in the PROWESS study with Factor V mutations were all heterozygous.

The remaining 3 FV Leiden carriers were enrolled from North America with either Hispanic or African ancestry.

Western Asians defined in the PROWESS study to include patients from Pakistan and the India subcontinent.